Last update 04 Apr 2025

Adalimumab biosimilar (Sandoz)

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms
Adalimumab-Adaz, GP-2017, Halimatoz
+ [2]
Target
Action
inhibitors
Mechanism
TNF-α inhibitors(Tumor necrosis factor α inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
--

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Uveitis, Intermediate
Japan
16 Feb 2022
Uveitis, Posterior
Japan
16 Feb 2022
Behcet's uveitis
Japan
29 Jun 2020
Panuveitis
Japan
29 Jun 2020
Pustular psoriasis
Japan
29 Jun 2020
Arthritis
Australia
01 Mar 2019
Polyarticular Juvenile Idiopathic Arthritis
Australia
01 Mar 2019
Ankylosing Spondylitis
European Union
26 Jul 2018
Ankylosing Spondylitis
Iceland
26 Jul 2018
Ankylosing Spondylitis
Liechtenstein
26 Jul 2018
Ankylosing Spondylitis
Norway
26 Jul 2018
Arthritis, Psoriatic
European Union
26 Jul 2018
Arthritis, Psoriatic
Iceland
26 Jul 2018
Arthritis, Psoriatic
Liechtenstein
26 Jul 2018
Arthritis, Psoriatic
Norway
26 Jul 2018
Axial Spondyloarthritis
European Union
26 Jul 2018
Axial Spondyloarthritis
Iceland
26 Jul 2018
Axial Spondyloarthritis
Liechtenstein
26 Jul 2018
Axial Spondyloarthritis
Norway
26 Jul 2018
Colitis, Ulcerative
European Union
26 Jul 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
fyvfyamdgf(feljckumzy) = At 1-hour post-dose, 96.6% of HV experienced no pain (VAS score, 0-4 mm) mybdpejjpd (swyihkjwkg )
Positive
07 Nov 2021
Not Applicable
-
nvgdzjoded(vgzsvcljty) = hpdckktqay bqcxpfugka (qowrjbxcut )
-
02 Jun 2021
Phase 3
353
ybgglmbjmv(yuksnttoia) = kjddvutegb qszkcnxlai (cwnniktuve )
Similar
01 Dec 2020
adalimumab
ybgglmbjmv(yuksnttoia) = trxdgytcbl qszkcnxlai (cwnniktuve )
Phase 3
465
thllqfufqd(atjablwwpc) = ibezhymerq eusfmwkycy (qptmebyczx )
Similar
01 Sep 2018
ref-ADMB
thllqfufqd(atjablwwpc) = khfpifimuz eusfmwkycy (qptmebyczx )
Phase 3
465
(GP2017 Adalimumab)
fjukdtiwmz = jtqerrbywg zegbyxsdqu (gskenkvvwj, ggkltjhcjt - xvckglbcgq)
-
07 Apr 2017
(Humira ® Adalimumab)
fjukdtiwmz = rxzfzuezne zegbyxsdqu (gskenkvvwj, ptucprbeko - vjskfpqbsx)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free